Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO 300 for Post-Acute COVID-19 Lung Function
NCT04482595Phase 2Active, not recruiting
- Sponsor
- Humanetics
- Start
- Nov 2020
- Primary completion
- Jul 2024
- Modality
- Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of BIO 300 in post-acute sequelae of SARS-CoV-2 infection (PASC), pulmonary fibrosis (PF), sponsored by Humanetics. Started Nov 2020; status: active, not recruiting.
02
Drugs
BIO 300
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT04482595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482595.